Gos­samer push­es ahead with failed asth­ma drug; Cull­gen gets $50M Se­ries B for pro­tein de­graders

Af­ter get­ting beat­en up by in­vestors over the key fail­ure of its lead drug GB001, Gos­samer had al­ready in­di­cat­ed that they thought they could move ahead in asth­ma, though like­ly through a part­ner­ship. And the biotech is push­ing for­ward on that front, ac­cord­ing to a Q4 state­ment to­day, fol­low­ing talks with reg­u­la­tors.

The com­pa­ny re­port­ed:

Gos­samer en­gaged with the FDA and the EMA about the clin­i­cal de­vel­op­ment path in asth­ma, and based off those in­ter­ac­tions, Gos­samer be­lieves that there is a vi­able clin­i­cal de­vel­op­ment path for GB001, or its back­up mol­e­cule, in asth­ma. Gos­samer does not cur­rent­ly plan to move for­ward with GB001, or its back­up mol­e­cule, in fur­ther clin­i­cal tri­als with­out a part­ner.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.